A Phase 4 interventional study of tacrolimus and mycophenolate mofetil in Graft Rejection, Kidney Failure and Kidney Transplantation, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2006-05-19.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.
Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 4th largest by enrollment, is one of 6 in phase 4, and was the 3rd registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 6 · Phase 4 6
First in 2003; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 50 across the 17 interventional studies. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
37 studies in Renal Insufficiency by Pfizer: 2 open now, 3 under way, none of them phase 3. Of 34 finished, 15 (44%) have results posted.
Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 4th largest by enrollment of the 36 interventional ones that give a count, is one of 8 in phase 4, and was the 7th registered.
Pfizer’s Renal Insufficiency studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing tacrolimus in Renal Insufficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 37 in Renal Insufficiency:
This tab as a report to print or save as PDF → With an account.
Evaluate renal graft function (based on the calculated Glomerular Filtration Rate) at 12 months after transplantation in patients receiving either a regimen of sirolimus plus mycophenolate mofetil following an antibody induction (RATG) or a standard regimen combining tacrolimus plus mycophenolate mofetil, both regimens including corticosteroids in patients undergoing renal allograft transplantation. In addition, the two treatment groups will be compared with respect to the incidence of acute rejection at 3, 6 and 12 months following transplantation, and the patient and graft survival at 6 and 12 months after transplantation. The safety of sirolimus plus mycophenolate mofetil following an antibody induction (ATG) will be evaluated beginning in the immediate post-operative period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
- Graft function as measured by Glomerular Filtration Rate (GFR) by Nankivell formula at Month 12 post-
transplantation.
Incidence of occurrence of primary acute rejection biopsy confirmed by a local pathologist using the 1997 Banff
criteria at 3, 6 and 12 Months following transplantation
One year graft biopsy status
Incidence of document infection
No study locations are listed for this record.
This study is completed, as verified in May 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tacrolimus · Mycophenolic Acid · Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →